Business Description
Onward Medical NV
ISIN : NL0015000HT4
Compare
Compare
Traded in other countries / regions
ONWD.BelgiumONWRF.USA63E.GermanyONWDb.UK IPO Date
2022-02-17Description
Onward Medical NV is a medical technology company developing and commercializing therapies to enable functional recovery for people with spinal cord injuries. It has developed two programmable neurostimulation platforms: an implantable system, ARCIM, and a non-invasive, transcutaneous system, ARCEX. The company has selected the United States and four European markets: Germany, France, the UK, and the Netherlands to create a customer base.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.76 | |||||
Equity-to-Asset | 0.41 | |||||
Debt-to-Equity | 0.94 | |||||
Debt-to-EBITDA | -0.5 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 24.3 | |||||
3-Year EPS without NRI Growth Rate | 29.3 | |||||
3-Year FCF Growth Rate | 21.2 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 91.43 | |||||
9-Day RSI | 77.9 | |||||
14-Day RSI | 68.84 | |||||
6-1 Month Momentum % | 49.87 | |||||
12-1 Month Momentum % | -6.89 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.7 | |||||
Quick Ratio | 4.7 | |||||
Cash Ratio | 4.46 | |||||
Days Payable | 717.06 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -72.3 | |||||
Shareholder Yield % | -1.17 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -103.54 | |||||
ROA % | -60.55 | |||||
ROIC % | -257.33 | |||||
ROC (Joel Greenblatt) % | -1647.58 | |||||
ROCE % | -66.4 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 9.09 | |||||
Price-to-Tangible-Book | 20.14 | |||||
EV-to-EBIT | -5.02 | |||||
EV-to-EBITDA | -5.12 | |||||
EV-to-FCF | -5.33 | |||||
Price-to-Net-Current-Asset-Value | 27.81 | |||||
Price-to-Net-Cash | 41.71 | |||||
Earnings Yield (Greenblatt) % | -19.92 | |||||
FCF Yield % | -17.48 |